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Abstract
Aim: To determine the benefits and risks of hepatic resection versus non-resectional liver-directed
treatments in patients with potentially resectable neuroendocrine liver metastases.
Methods: A systematic review identified 1594 reports which alluded to a possible liver resection for
neuroendocrine tumour metastases, of which 38 reports (all retrospective), comprising 3425 patients,
were relevant.
Results: Thirty studies reported resection alone, and 16 studies reported overall survival (OS). Only two
studies addressed quality-of-life (QoL) issues. Five-year overall survival was reported at 41–100%,
whereas 5-year progression-free survival (PFS) was 5–54%. We identified no robust evidence that a liver
resection was superior to any other liver-directed therapies in improving OS or PFS. There was no
evidence to support the use of a R2 resection (debulking), with or without tumour ablation, to improve
either OS or QoL. There was little evidence to guide sequencing of surgery for patients presenting in Stage
IV with resectable disease, and none to support a resection of asymptomatic primary tumours in the
presence of non-resectable liver metastases.
Conclusion: Low-level recommendations are offered to assist in the management of patients with
neuroendocrine liver metastases, along with recommendations for future studies.
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Introduction
Neuroendocrine tumours (NETs) frequently metastasise to the
liver. Numerous treatment options have been used both for cure
and disease control. Surgical treatment consists of curative resec-
tion, palliative cytoreductive resection and transplantation.
Owing to various factors, a complete surgical resection is possible
only in a minority of people with neuroendocrine liver metastases
(NLMs). Ablative therapies may also be used, either as an adjunct
to surgery or as a primary treatment. A hepatectomy is the only
potentially curative treatment for NLMs, but there are few pro-
spective studies comparing modalities of treatment.1 A Cochrane
review2 concluded that there was insufficient evidence comparing
surgical resection to other treatment modalities, and therefore
surgical resection remains the standard of care whenever possible.
Hepatic metastases occur in 50–75% of patients with NET. A
complete resection of such hepatic metastases is feasible in only
7–15% of patients.3 Until now, surgical management was consid-
ered the best approach for resectable hepatic metastases fromNET
in terms of symptom relief and prolonged survival, in spite of the
high incidence of recurrence after surgery.4Advances in technology
have led to the development of new liver-directed therapies includ-
ing ablative techniques, transarterial chemoembolization (TACE)
or selective internal radiation therapy (radioembolization), which
have been shown to be effective in slowing tumour progression and
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palliating symptoms.5,6 The treatment of hepatic metastases from
NET has therefore evolved into a more diverse multimodal
approach, where the role of surgery should be reappraised.
The aim of this review was to determine the benefits and risks
of a hepatic resection versus non-resectional liver-directed treat-
ments in patients with potentially resectable NET liver metastases.
Since this work was done in the context of the 2012 international
consensus conference on NLMs in London, it does not cover the
role of liver transplantation which was reviewed by another expert
group and published separately.
Materials and methods
Definitions
Resectability of NET tumour metastatic to the liver depends on
both technical-anatomic considerations and also on tumour
biology. There is general agreement that a liver resection for meta-
static NET should be considered as a debulking procedure.7 As a
consequence, the assessment of resectability of liver metastases
from NET can lead to different conclusions depending on techni-
cal judgment regarding anatomic versus non-anatomic removal of
all tumour deposits, or in the general setting of a hepatic resection
when the natural history of the disease is taken into account. In
this review, unless otherwise specified, resectability is intended to
be the removal of all NET metastases within the liver parenchyma
by means of surgical interventions with curative intent.
Methods
Since this review was prepared for the 2012 international consen-
sus conference on NLMs in London, the literature search was
organized and centralized by the organizing committee of the
conference. Librarians of the Medical Library Careum, University
of Zurich, Switzerland, developed the electronic search strategy to
query databases and to identify all potentially relevant articles.
The following databases were searched: Medical Literature Analy-
sis and Retrieval System Online, Excerpta Medica Database, and
the Cochrane Library (Cochrane Database of Systematic Reviews,
Database of Abstracts of Reviews of Effects, and Cochrane Central
Register of Controlled Trials). Titles and/or abstracts of all iden-
tified records were independently screened by twomembers of the
review team to ascertain their relevance. The full text of each of
these potentially relevant studies was then assessed for eligibility.
Any disagreement was resolved through discussion with a third
review team member. Additional articles were retrieved through
manual search or scanning of reference lists. No language or pub-
lication date restrictions were imposed on the literature search.
The participants/population studied included patients who
underwent hepatic surgery, or any other treatment for resectable
hepatic metastases from NET. Studies that did not report overall
survival (OS) were excluded. The intervention(s), exposure(s)
reviewed included: hepatic resection, local ablative techniques,
peptide receptor radionuclide treatment, chemotherapy and
biotherapy. The primary outcome considered was OS after treat-
ment for resectable hepatic metastases from NET, with secondary
outcomes including progression-free survival (PFS) and quality of
life (QoL).
Level of evidence and strength of recommendation were graded
according to the grades of recommendation, assessment, develop-
ment and evaluation (GRADE) system, which allows a separate
rating of the quality of evidence and grading for the strength of
recommendations.8 It offers four levels of evidence quality: high,
moderate, low and very low.
The systematic reviews were prospectively registered with the
International Prospective Register of Systematic Reviews
CRD420120026529 and the study methodology adhered to the
preferred reporting items for systematic reviews and meta-
analyses (PRISMA). The full research strategy was published
elsewhere.10
Results
Figure 1 shows the flow chart of study selection. From a total of
1594 studies identified by the search strategy, 38 studies were
included in this review. No studies were randomized controlled
trials. All of them were retrospective including 11 comparative
Literature search
  Databases: Medline, EMBASE, and the Cochrane Library
  Limits: Adult humans, no language or publication year
               restrictions
Excluded (n = 1467)
  Duplicates (n = 482)
  Wrong subject (n = 485)
  Wrong study design (n = 400)
  Non-surgical treatment only (n = 100)
Excluded (n = 78)
  Does not address the question (n = 23)
  No specific survival reported (n = 24)
  Wrong design, duplicates, not found (n = 31)
Search results combined (n = 1594)
Articles screened on basis of title and abstract
Included (n = 128)
Included (n = 38)
Manuscript review and application of inclusion criteria
Figure 1 PRISMA (preferred reporting items for systematic reviews
and meta-analyses) flow chart showing selection of the studies for
review
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cohort studies11–21 and 27 case-series.7,22–47 Overall, 20 studies were
performed in USA, 14 in Europe (7 in France, 4 in Germany, 2 in
UK, 1 in Italy), 3 in Australia and 1 in Japan, comprising 3425
patients. Thirty studies (79%) included a group of patients who
only underwent a hepatic resection. In the other studies, hepatic
resections were always combined with either radiofrequency abla-
tion (RFA) or cryoablation, which confounds interpretation of
reported outcomes. Only 16 studies (42%) reported 5-year OS
and only 5 (13%) reported 5-year PFS. Quality of life after surgery
was assessed formally in only two studies.18,36 After a hepatic resec-
tion alone, 5-year survival was reported between 41% and 100%,
and 5-year PFS between 5% and 54%.
Does potentially curative (R0) resection improve OS?
Is there any evidence to suggest that a hepatic resection with
curative intent (R0/R1) improves outcomes (tumour-free sur-
vival, OS, QoL) for patients with resectable NLMs, when
compared with non-surgical treatment (locally ablative tech-
niques, percutaneous liver-directed techniques, peptide receptor
radionuclide treatment, chemotherapy, targeted therapy or
biotherapy)?
When considering a liver resection for these patients, the points
to be considered include selection bias of patients reported under-
going a liver resection, defining R0 resection and an acceptable
definition of ‘debulking’ (and what would be considered accept-
able in terms of symptom control?), and the comparator pro-
cedures including transplantation.
As shown in Table 1, only 10 studies compared a hepatic resec-
tion with other treatments for resectable hepatic metastases from
NET,11–14,16–21 and only 3 of these studies reported more than 100
patients.13,16,18 All of these studies were retrospective and uncon-
trolled. Consequently, patient groups were heterogeneous in most
Table 1 Retrospective studies comparing liver resection with other treatments for neuroendocrine liver metastases








Saxena et al., 2012a19 17 Liver resection (10) 79 22
Radioembolization (15) NR 18
Systemic chemotherapy (14) 18 6
Conservative therapy (11) 59 16
Karabulut et al., 201113 123 Liver resection (29) 190 15
RFA (69) 73 10.5
Embolization (29)
(TAE, TACE or SIRT)
33 6.5




Landry et al., 200814 54 Liver resection ± ablation (23) 75% NA
No liver resection (31) 62% NA
Musunuru et al., 200617 48 Liver resection ± RFA (13) 83% (3-year OS) NA
Embolization (18) 31% (3-year OS) NA
Conservative (17) 31% (3-year OS) NA
Osborne et al., 200618 120 Cytoreduction (61) 43 (mean OS) NA
Embolization (59) 24 (mean OS) NA
Touzios et al., 200520 60 Liver resection ± ablation (19) 72% NA
TACE ± resection (18) 50% NA
Conservative (23) 25% NA
Yao et al., 201121 36 Liver resection (16) 70% NA
TACE (20) 40% NA
Chamberlain et al., 200011 85 Liver resection (34) 76% NA
Embolization (33) 50% NA
Conservative (18) 39% (3-year OS) NA
Chen et al., 199812 38 Liver resection (15) 73% NA
Conservative (23) 29% NA
NR, not reached; NA, not available.
aSaxena et al. compared different types of treatments of liver recurrence after initial surgery.
OS, overall survival; PFS, progression-free survival; TAE, transarterial embolization; TACE, transarterial chemoembolization; RFA, radiofrequence
ablation; SIRT, Selective internal radiation therapy.
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of these studies. In four studies, patients included within the
hepatic resection groups actually underwent a partial hepatectomy
and ablation,14,17,20 or resection was considered incomplete
(cytoreduction).18 In most studies combining resection and
embolization, patients underwent either transarterial emboliza-
tion (TAE), TACE or radioembolization.11,13,16–18 Finally, patients
included in the conservative or non-resection treatment groups
underwent either chemotherapy, radiotherapy or received
octreotide.
All studies suffered from a bias of patient selection. Indeed,
patients who underwent non-surgical treatment had a greater
tumour burden, larger tumours and a higher incidence of bilobar
disease. Therefore, the relatively greater survivals reported after a
surgical resection compared with patients who underwent
embolization or conservative treatment should be interpreted
with caution. Four studies showed significantly greater OS after
a hepatic resection compared with other treatments, but only with
univariate analysis.12,17,18,20 With multivariate analysis, the type of
treatment was never associated with improved survival. Of note,
the most frequent and significant adverse correlate of survival was
the presence of extra-hepatic disease.13,16,19
A comparison of PFS between treatment groups was only avail-
able in two studies.13,19 Saxena et al.19 showed that independent
factors for PFS included histological grade, extra-hepatic disease
and type of treatment. However, these series focused on the man-
agement of a hepatic recurrence of metastatic NET after initial
surgical treatment. In the study by Karabulut et al.,13 treatment
modality was neither an independent factor for PFS or OS. Only
one study assessed QoL among treatment groups using the
patient’s Eastern Cooperative Oncology Group (ECOG) perfor-
mance status.18 Patients who underwent embolization had a sig-
nificant decrease in performance status after treatment compared
with patients who underwent cytoreductive surgery. However,
patients who underwent embolization had more diffuse hepatic
disease.
In conclusion, although a hepatic resection is currently the
mainstay of curative treatment for resectable metastases from
NET, there is no robust evidence that it is superior to other liver-
directed or systemic therapies (GRADE level of evidence: low).
Is there a role for R2 (debulking) surgery?
Does a R2 hepatic resection (debulking) improve the outcome
(PFS, OS, QoL) in patients with NET liver metastases, when com-
pared with non-surgical treatment (locally ablative techniques, per-
cutaneous liver-directed techniques, peptide receptor radionuclide
treatment, chemotherapy, targeted therapy or biotherapy)?
Only one study was identified which addressed this question.18
In the study by Osborne et al.,18 38 patients underwent a curative
resection, 23 had cytoreductive surgery (R2) and 59 were treated
with TAE. Considering patient selection bias, the mean survival in
patients who underwent palliative cytoreduction was 32 com-
pared with 24 months in patients treated with embolization
(P < 0.001). Patients who underwent curative surgery had the best
mean survival (50 months). As stated previously patient perfor-
mance status after treatment was worse in the embolization group.
There is no evidence that a R2 hepatic resection improves sur-
vival or QoL when compared with TAE (GRADE level of evidence:
low). No comparison is available between a R2 liver resection and
peptide receptor radionuclide treatment.
Is there any role for tumour ablation as an adjunct to
R2 (debulking) surgery?
In patients with hepatic metastases from NET, do locally ablative
techniques as an adjunct to a R2 liver resection improve outcome
(PFS, OS, QoL)?
We did not identify any study which may answer this question.
There is no evidence that locally ablative techniques, as an adjunct
to a R2 hepatic resection, improve the outcome of patients with
hepatic metastases from NET (GRADE level of evidence: nil).
Sequencing of surgery for primary and metastases if
both resectable
In patients with both synchronously resectable primary NET and
hepatic metastases, should the primary or the hepatic metastases
be resected first or together to improve outcome (PFS, OS, QoL)?
There is no comparative study designed to answer this specific
question. However, some data can be extracted from retrospective
studies.11,16,21,22,29,47 Four studies reported that an initial resection of
the primary NET was associated with prolonged survival on
univariate analysis.11,16,21,22 In two of these studies,16,22 an initial
resection of the primary NET remained an independent factor
associated with survival on multivariate analysis. Only one study
did not show any benefit on survival of resection of the primary
NET, but the small number of patients who did not have resection
of their primary NET precluded a definitive conclusion on the
impact of a resection of the primary NET on survival.47
More recently, Gaujoux et al.29 showed in a series of 36 patients
that synchronous resection of a primary tumour and hepatic
metastases can be performed with low mortality (3%). Addition-
ally, most patients developed recurrence in the liver which was
amenable to subsequent ablative therapies allowing on-going
disease control. There are no studies which address the outcome of
a hepatic resection of metastatic NET first before subsequent
resection of the primary NET on survival.
Little evidence suggests that resection of the primary NET in
patients with resectable hepaticmetastases improves survival. There
is insufficient data to support whether resection of the primary
NET, either initial to or concomitant with resection of hepatic
metastases, affects outcomes (GRADE level of evidence: low).
Recommendations
Hepatic resection has been widely employed for metastatic NET.
Current data show that a hepatic resection of metastatic NET,
whether metachronous to, or synchronous with resection of the
primary NET, can be performed with limited and clinically
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acceptable operative risk. However, the efficacy of such treatment,
based either on comparative non-operative controls or alternative
non-resective treatments on similarly matched patient cohorts,
remains unproven.
Hepatic resection with/without ablation could be offered to
patients with liver limited/dominant metastatic NETs with
intended curative/long-term survival benefit provided they fulfil
the following criteria (Level of recommendation: Low):
1 The primary tumour is resected or resectable (along with any
possible draining lymph node involvement).
2 The patient is both fit for and willing to consider a hepatic resec-
tion (and in particular has no significant untreated carcinoid
cardiac disease that would preclude a safe hepatic resection).
3 The liver disease can be macroscopically resected/ablated with
the preservation of enough functional disease-free liver
remnant according to the body surface area of the patient.
4 All identified hepatic disease can be resected/ablated with cura-
tive intent.
Future reports addressing hepatic resection for metastatic NET
should include:
a. Details regarding resection of the primary NET – site, type
of resection, local-regional stage of the primary NET, date of
resection of the primary NET, type of interim therapy before
resection of hepatic metastases if metachronous presentation
of the latter and timing from initial diagnosis of NET, func-
tional status of the primary NET.
b. The development of a quantitative (or at least semi-
quantitative) hepatic staging system to provide a rational basis
for future treatment protocols and outcome assessment. Simi-
larly, regarding R1 versus R2 resection definitions.
c. Details regarding resection of the metastatic NET – type of
hepatic resection, extent of hepatic resection (R0, R1, R2),
descriptors of R2 disease, type of concurrent ablative treat-
ments, extent of combined treatments (R0, R1, R2), presence
or absence of extrahepatic metastases, mechanism of docu-
mentation of extrahepatic disease (imaging, intra-operative
observation, biopsy, etc).
d. Details of adjunctive treatments – type and number of non-
resective treatments, indication for non-resective treatment
(neoadjuvant, adjunctive, adjuvant).
e. Development of a registry based on the recommended data-
base so that prospectively acquired data can be generated to
detail operative risks and outcomes. This database should also
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